Citius Pharma reports $5.6M revenue from LYMPHIR launch and secures $41.5M financing to expand commercial efforts.

Citius Pharmaceuticals' subsidiary, Citius Oncology, generated $5.6 million in net revenue in the first half of fiscal 2026 from the launch of LYMPHIR, an FDA-approved immunotherapy for certain lymphoma patients. The company secured up to $36.5 million in debt and equity financing, alongside a $5 million direct offering by Citius Pharma, to fund commercial expansion and build out the sales force. LYMPHIR has near 100% payer coverage and is gaining formulary access in 83% of target accounts, with patients transitioning from academic centers to community infusion centers. Positive early clinical data supports LYMPHIR's potential in combination therapies, while Citius Pharma continues to advance other pipeline products with the FDA.